mRNA-1195: a Phase 2 safety study of an experimental Epstein-Barr virus vaccine in early MS
Published by MyelinWatch:
mRNA-1195 · Infection with Epstein-Barr virus (EBV), a very common virus, is among the strongest known risk factors for MS. mRNA-1195 is an experimental mRNA injection made by ModernaTX; the company's earlier Phase 1 registry record describes it as an EBV candidate vaccine. This Phase 2 study gives it to adults aged 18 to 55 who already have MS or an early form of it: relapsing MS, a first attack (clinically isolated syndrome) or MRI findings typical of MS without symptoms (radiologically isolated syndrome), diagnosed within the previous 24 months, in people who already carry EBV. Participants receive three injections into the muscle, at 0, 2 and 6 months, of a low dose, a high dose or a placebo, without knowing which.
What is being studied
Infection with Epstein-Barr virus (EBV), a very common virus, is among the strongest known risk factors for MS. mRNA-1195 is an experimental mRNA injection made by ModernaTX; the company's earlier Phase 1 registry record describes it as an EBV candidate vaccine. This Phase 2 study gives it to adults aged 18 to 55 who already have MS or an early form of it: relapsing MS, a first attack (clinically isolated syndrome) or MRI findings typical of MS without symptoms (radiologically isolated syndrome), diagnosed within the previous 24 months, in people who already carry EBV. Participants receive three injections into the muscle, at 0, 2 and 6 months, of a low dose, a high dose or a placebo, without knowing which.
Research stage
Testing whether it helps patients
The current listing is open to participants.
What we know so far
There are no results yet. The study's main goals are all about safety and tolerability: reactions at the injection site and in the whole body, other side effects, side effects needing medical attention, and serious side effects. MRI lesions, new disease activity, antibody levels and disability (EDSS) are secondary measures. ClinicalTrials.gov lists an estimated 180 participants, a start on 16 April 2025 and estimated primary completion on 8 January 2029. An earlier Phase 1 study of mRNA-1195 in 482 healthy adults (NCT05831111) is listed as completed on 14 October 2026, with no results posted.
What this means for patients today
mRNA-1195 is an experimental product in a study, not an available treatment or a proven way to prevent or control MS. That the registry lists the study as accepting participants says nothing about whether it works or is safe. The study is small, with an estimated 180 people, and is designed mainly to check safety. It lists 17 sites in the United States, the United Kingdom and Australia, two of them shown as terminated; no site in Greece is listed. People who have had myocarditis or pericarditis, or who took immunosuppressive medicines in the previous 30 days, are excluded; eligibility must be confirmed with a study team.
Next documented step
ClinicalTrials.gov estimates primary completion on 8 January 2029.
- Treatment or approach
- Experimental mRNA injection that an earlier registry record describes as an Epstein-Barr virus candidate vaccine, tested in early relapsing MS
- How it is intended to work
- Experimental mRNA injection described in its Phase 1 registry record as an Epstein-Barr virus candidate vaccine
- Where the study is running
- Listed sites are in the United States, the United Kingdom and Australia; no site in Greece is listed
- Published by MyelinWatch
- Last substantive MyelinWatch update